<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/22/brokerages-anticipate-intersect-ent-inc-nasdaqxent-to-post-0-33-earnings-per-share.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-22T18:35:04+00:00"/>
    <meta property="og:title" content="Brokerages Anticipate Intersect ENT Inc (NASDAQ:XENT) to Post -$0.33 Earnings Per Share"/>
    <meta property="og:description" content="Equities analysts forecast that Intersect ENT Inc (NASDAQ:XENT) will report earnings per share of ($0.33) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Intersect ENT’s earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.37). Intersect ENT reported earnings per share of ($0.16) during the same quarter […]"/>
  </head>
  <body>
    <article>
      <h1>Brokerages Anticipate Intersect ENT Inc (NASDAQ:XENT) to Post -$0.33 Earnings Per Share</h1>
      <address><time datetime="2019-11-22T18:35:04+00:00">22 Nov 2019, 18:35</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/intersect-ent-inc-logo.jpg"/>
      </figure>
      <p>Equities analysts forecast that Intersect ENT Inc (NASDAQ:XENT) will report earnings per share of ($0.33) for the current fiscal quarter, according to <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks</a>. Five analysts have issued estimates for Intersect ENT’s earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.37). Intersect ENT reported earnings per share of ($0.16) during the same quarter last year, which would suggest a negative year over year growth rate of 106.3%. The company is expected to issue its next quarterly earnings report on Monday, February 24th.</p>
      <p>According to Zacks, analysts expect that Intersect ENT will report full year earnings of ($1.45) per share for the current fiscal year, with EPS estimates ranging from ($1.50) to ($1.32). For the next year, analysts expect that the firm will report earnings of ($1.40) per share, with EPS estimates ranging from ($1.55) to ($1.10). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Intersect ENT.</p>
      <p>Intersect ENT (NASDAQ:XENT) last announced its quarterly earnings data on Friday, November 1st. The medical equipment provider reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.01). The company had revenue of $24.06 million during the quarter, compared to analyst estimates of $24.08 million. Intersect ENT had a negative net margin of 36.37% and a negative return on equity of 34.19%. Intersect ENT’s revenue was down 2.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.25) earnings per share.</p>
      <p>Several equities analysts have weighed in on the company. Piper Jaffray Companies set a $21.00 price objective on Intersect ENT and gave the company a “hold” rating in a report on Friday, November 1st. BidaskClub raised Intersect ENT from a “sell” rating to a “hold” rating in a report on Friday, October 11th. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=XENT">ValuEngine</a> raised Intersect ENT from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 3rd. Finally, Guggenheim cut Intersect ENT from a “buy” rating to a “neutral” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, eight have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. Intersect ENT presently has an average rating of “Hold” and a consensus target price of $27.68.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/XENT/earnings/">NASDAQ XENT</a> traded down $0.12 during midday trading on Friday, hitting $21.23. The company had a trading volume of 257,067 shares, compared to its average volume of 379,517. The company has a market capitalization of $673.16 million, a PE ratio of -27.93 and a beta of 0.68. The firm has a 50-day moving average price of $18.92 and a 200-day moving average price of $20.35. Intersect ENT has a twelve month low of $14.61 and a twelve month high of $35.87.</p>
      <p>In other news, insider Robert H. Binney, Jr. sold 25,584 shares of the business’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $21.54, for a total transaction of $551,079.36. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at <a href="https://www.sec.gov/Archives/edgar/data/1271214/000156218019005398/xslF345X03/primarydocument.xml">the SEC website</a>. 5.90% of the stock is currently owned by insiders.</p>
      <p>Institutional investors have recently bought and sold shares of the company. Quadrant Capital Group LLC acquired a new position in shares of Intersect ENT during the 3rd quarter worth $36,000. Quantamental Technologies LLC raised its holdings in shares of Intersect ENT by 133.6% during the 2nd quarter. Quantamental Technologies LLC now owns 4,555 shares of the medical equipment provider’s stock worth $104,000 after buying an additional 2,605 shares in the last quarter. Nisa Investment Advisors LLC bought a new stake in Intersect ENT during the 3rd quarter worth $208,000. Cubist Systematic Strategies LLC grew its position in Intersect ENT by 106.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 18,013 shares of the medical equipment provider’s stock worth $410,000 after acquiring an additional 9,275 shares during the last quarter. Finally, A.R.T. Advisors LLC bought a new stake in Intersect ENT during the 2nd quarter worth $539,000. 97.96% of the stock is owned by institutional investors.</p>
      <p>
        <b>About Intersect ENT</b>
      </p>
      <p>Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.</p>
      <p>Recommended Story: <a href="https://www.marketbeat.com/financial-terms/capital-gains-401k-ira/">What is a capital gain?</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=XENT">Get a free copy of the Zacks research report on Intersect ENT (XENT)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=XENT"/>
      </figure>
    </article>
  </body>
</html>